The Rare Disease Endpoint Advancement (RDEA) Program: A Game-Changer for Clinical Trials in the Healthcare Industry
Learn how the FDA’s RDEA program supports novel efficacy endpoints, accelerating drug development and enhancing collaboration between healthcare companies and regulatory bodies.
)%20(5).png)
